Shadi Daoud, MD
Cardiovascular Disease · Las Vegas, NVNPI 1699739151
Payments from drug & device makers
Across 408 payments — averaging $74.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$17K
- AstraZeneca$5K
- Abbott$2K
- E.r. Squibb & Sons, L.L.C.$934
- Amgen$611
- Abiomed$599
- plus $5K from 33 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 82 | $16,720 |
| AstraZeneca | 18 | $4,731 |
| Abbott | 21 | $1,877 |
| E.r. Squibb & Sons, L.L.C. | 51 | $934 |
| Amgen | 41 | $611 |
| Abiomed | 10 | $599 |
| Medtronic(2 entities) | 7 | $544 |
| Boehringer Ingelheim | 23 | $533 |
| Novo Nordisk | 25 | $511 |
| Pfizer | 24 | $426 |
| Philips North America LLC | 17 | $422 |
| Edwards Lifesciences | 7 | $304 |
| Boston Scientific | 6 | $265 |
| Merck | 12 | $244 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $193 |
| Johnson & Johnson | 11 | $167 |
| Biosense Webster, Inc. | 4 | $163 |
| Bridgebio Pharma, Inc. | 4 | $111 |
| Itamar Medical Inc | 2 | $108 |
| Kiniksa Pharmaceuticals, Ltd. | 6 | $97 |
| Alnylam Pharmaceuticals Inc. | 3 | $88 |
| Lantheus Medical Imaging, Inc. | 4 | $83 |
| Kowa Pharmaceuticals America, Inc. | 3 | $70 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $55 |
| Bayer | 3 | $54 |
| Lexicon Pharmaceuticals, Inc. | 2 | $53 |
| Heartflow, Inc. | 2 | $51 |
| Cvrx, Inc. | 2 | $51 |
| Atricure, Inc. | 2 | $45 |
| Impulse Dynamics (USA) Inc. | 1 | $30 |
| Teleflex LLC | 1 | $27 |
| Actelion Pharmaceuticals US, Inc. | 1 | $24 |
| Esperion Therapeutics, Inc. | 1 | $21 |
| Irhythm Technologies, Inc. | 1 | $21 |
| Shockwave Medical, Inc | 1 | $20 |
| Lilly USA, LLC | 1 | $19 |
| Vifor Pharma, Inc. | 1 | $18 |
| Baxter Healthcare | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
How this compares
$30,323 in reported general payments places this provider in the 85th percentile of 165 cardiovascular disease providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Las Vegas
- Ramprasad DandillayaLas Vegas$1.8M
- Chowdhury AhsanLas Vegas$1.4M
- Arjun GururajLas Vegas$399K
- Navid KazemiLas Vegas$156K
- Branavan UmakanthanLas Vegas$109K
- Sanjay MalhotraLas Vegas$101K
- Jawad KianiLas Vegas$73K
- Amish PrasadLas Vegas$58K
- Rafael ValenciaLas Vegas$52K
- Salvador BorromeoLas Vegas$45K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.